PolyPid Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsPolyPid Ltd. is a clinical-stage biopharmaceutical company developing long-acting, controlled-release therapies, with its lead candidate D-PLEX 100 in Phase 3 for surgical site infection prevention.
What they do
PolyPid develops long-acting, controlled-release medicines delivered at the site of care. Its lead product candidate, D-PLEX 100, uses proprietary PLEX technology to release doxycycline locally for 30 days following surgical implantation, aiming to prevent surgical site infections. The company has a pipeline spanning surgical care and metabolic diseases, though D-PLEX 100 is the most advanced asset.
Revenue drivers
- D-PLEX 100 (product candidate) — No approved products; potential future revenue depends on regulatory approval and commercialization of this lead candidate for SSI prevention.
- Other pipeline programs — Early-stage programs in metabolic diseases and other indications; no near-term revenue contribution.
- No current product sales — The company has no marketed products, so revenue is currently zero; operations funded by equity offerings and debt.
Recent performance
For fiscal year 2025, PolyPid reported a net loss of $34.2 million, compared to a net loss of $29.0 million in 2024. Operating cash flow was negative $27.9 million in 2025, versus negative $22.0 million in 2024. Diluted EPS was $2.09 in 2025, down from $4.91 in 2024, reflecting a higher share count. As of December 31, 2025, the company held $6.4 million in cash and equivalents, with total assets of $22.3 million and shareholders' equity of $11.0 million.
Strategy
PolyPid is focused on advancing D-PLEX 100 through regulatory approval, leveraging positive topline results from the pivotal SHIELD II Phase 3 trial announced in June 2025. The company plans to submit a New Drug Application (NDA) to the FDA and pursue commercialization in the U.S. It also continues to invest in its PLEX technology platform for other therapeutic areas. The strategy aims to address unmet needs in surgical care and beyond, with a focus on improving patient outcomes.
Risks
- Clinical and regulatory risk — D-PLEX 100 has not yet received FDA approval; failure to obtain approval would significantly impair the company's prospects.
- Liquidity risk — With only $6.4 million in cash and negative operating cash flow of $27.9 million in 2025, the company may need to raise additional capital to fund operations and milestone milestones.
- Commercialization risk — Even if approved, PolyPid has no commercial infrastructure and would face challenges in marketing D-PLEX 100 against established standard-of-care antibiotics.
- Dilution risk — Raising capital through equity offerings could dilute existing shareholders, as evidenced by the sharp decline in diluted EPS from $4.91 in 2024 to $2.09 in 2025.
Outlook
Management expects to submit an NDA for D-PLEX 100 following the positive SHIELD II results, with potential approval and launch in the coming years. The company will need to secure additional funding to support regulatory activities and pre-commercial planning. Near-term focus is on completing the regulatory process and preparing for potential commercialization in the U.S. market.